Literature DB >> 12220577

Acute administration of phencyclidine induces tonic activation of medial prefrontal cortex neurons in freely moving rats.

Y Suzuki1, E Jodo, S Takeuchi, S Niwa, Y Kayama.   

Abstract

Recent studies have reported that acute administration of the psychotomimetic drug phencyclidine results in considerable increases in the amounts of both extracellular glutamate and dopamine in the medial prefrontal cortex (mPFC). However, the effect of phencyclidine on the firing activity of mPFC neurons remains unknown. Here, we report the first data on phencyclidine-induced activation of mPFC neurons in freely moving rats. Unanesthetized rats received an intraperitoneal injection of either phencyclidine (5 mg/kg) or physiological saline (0.5 ml/kg) in order to investigate the impulse activity of mPFC neurons and behavioral activity. The phencyclidine injection induced a remarkable increase (two-fold or more) in the spontaneous discharge rate of the majority of mPFC neurons (20/23), and this increase lasted for more than 70 min. In addition, a considerable augmentation of behavioral activity was observed that nearly paralleled that of the mPFC neuronal activation. In contrast, microiontophoretically applied phencyclidine exerted little influence on the spontaneous firing activity of most mPFC neurons (25/29) in anesthetized rats, although systemically applied phencyclidine produced activation of mPFC neurons even under general anesthesia. These results suggest that the behavioral abnormalities induced by acute administration of phencyclidine may be caused by hyperactivation of mPFC neurons, and that this hyperactivation is elicited through excitatory inputs from brain regions outside the mPFC. Copyright 2002 IBRO

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12220577     DOI: 10.1016/s0306-4522(02)00298-1

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  39 in total

Review 1.  GABAergic interneuron origin of schizophrenia pathophysiology.

Authors:  Kazu Nakazawa; Veronika Zsiros; Zhihong Jiang; Kazuhito Nakao; Stefan Kolata; Shuqin Zhang; Juan E Belforte
Journal:  Neuropharmacology       Date:  2011-01-26       Impact factor: 5.250

2.  Ketamine disrupts θ modulation of γ in a computer model of hippocampus.

Authors:  Samuel A Neymotin; Maciej T Lazarewicz; Mohamed Sherif; Diego Contreras; Leif H Finkel; William W Lytton
Journal:  J Neurosci       Date:  2011-08-10       Impact factor: 6.167

3.  NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons.

Authors:  Houman Homayoun; Bita Moghaddam
Journal:  J Neurosci       Date:  2007-10-24       Impact factor: 6.167

4.  Sertindole restores attentional performance and suppresses glutamate release induced by the NMDA receptor antagonist CPP.

Authors:  Mirjana Carli; Eleonora Calcagno; Ester Mainini; Jorn Arnt; Roberto W Invernizzi
Journal:  Psychopharmacology (Berl)       Date:  2010-11-04       Impact factor: 4.530

5.  Impaired cognition after stimulation of P2Y1 receptors in the rat medial prefrontal cortex.

Authors:  Holger Koch; Anton Bespalov; Karla Drescher; Heike Franke; Ute Krügel
Journal:  Neuropsychopharmacology       Date:  2014-07-15       Impact factor: 7.853

6.  THC and endocannabinoids differentially regulate neuronal activity in the prefrontal cortex and hippocampus in the subchronic PCP model of schizophrenia.

Authors:  David D Aguilar; Andrea Giuffrida; Daniel J Lodge
Journal:  J Psychopharmacol       Date:  2015-10-28       Impact factor: 4.153

7.  Subanalgesic ketamine enhances morphine-induced antinociceptive activity without cortical dysfunction in rats.

Authors:  Hiroki Shikanai; Sachiko Hiraide; Hidekazu Kamiyama; Tsukasa Kiya; Koji Oda; Yoshikazu Goto; Yoshiki Yanagawa; Kei-ichi Shimamura; Yukiko Goda; Hiroko Togashi
Journal:  J Anesth       Date:  2013-10-11       Impact factor: 2.078

8.  Differential Effects of Anaesthesia on the phMRI Response to Acute Ketamine Challenge.

Authors:  Duncan J Hodkinson; Carmen de Groote; Shane McKie; J F William Deakin; Steve R Williams
Journal:  Br J Med Med Res       Date:  2012-09

9.  The hippocampo-prefrontal pathway: a possible therapeutic target for negative and cognitive symptoms of schizophrenia.

Authors:  Ayan Ghoshal; P Jeffrey Conn
Journal:  Future Neurol       Date:  2015

10.  NMDA antagonist and antipsychotic actions in cortico-subcortical circuits.

Authors:  Lucila Kargieman; Noemí Santana; Guadalupe Mengod; Pau Celada; Francesc Artigas
Journal:  Neurotox Res       Date:  2008-10       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.